Definitive Radiation Therapy For Stage I NSCLC

Loading...

From the course by University of Michigan

Thoracic Oncology

130 ratings

University of Michigan

Thoracic Oncology

130 ratings

Thoracic malignancies are major, global health problems. Lung cancer is the most common cancer and cause of cancer death in the world, with more than 1.5 million deaths per year. More Americans will die from lung cancer each year (approximately 159,480) than from colon, breast, pancreatic, and prostate cancer combined (approximately 158,630), the next most common causes of cancer death. Esophageal cancer is the 6th most common cause of cancer deaths worldwide, and the 4th most common cause in developing nations. This course will provide a comprehensive, multidisciplinary introduction to state of the art approaches in the care of patients with thoracic malignancies, including various types of lung cancers and esophageal cancers. Didactic material will cover epidemiology, screening and diagnosis, staging, imaging, radiation therapy, systemic therapy, surgery, psychiatry, and patient support topics. This is an on-demand course with integrated learning units that are focused on specific topics. Each unit contains several video lectures with interactive questions and is followed by a short quiz. Prerequisites: None required although basic medical training in some field related to thoracic oncology would be helpful.

From the lesson

Non-Small Cell Lung Cancer and Tracheal Cancer: Therapeutics

After reviewing this unit, the learner will understand basic principles regarding:

Introduction to Radiation Therapy13:10

Definitive Radiation Therapy For Stage I NSCLC13:00

Definitive Radiation Therapy For Locally Advanced NSCLC21:33

Palliative Radiation Therapy For Metastatic Lung Cancer17:45

Stereotactic Body Radiation Therapy (SBRT) For Oligometastatic Lung Cancer10:28

Adjuvant Therapy for Non-Small Cell Lung Cancer14:58

Combined Modality Therapy For Locally Advanced Non-Small Cell Lung Cancer17:01

Overview of Stage IV Non-Small Cell Lung Cancer14:05

Chemotherapy for Stage IV Non-Small Cell Lung Cancer30:23

Immunotherapy for Non-Small Cell Lung Cancer19:03

Molecularly Targeted Therapy for Non-Small Cell Lung Cancer28:03

FDG-PET Imaging of Non-Small Cell Lung Cancer: Treatment Response Monitoring9:52

Early Stage: Surgery - Lung Resection - Wedge, Segmentectomy, Lobectomy15:01

Complex Lung Resection: Sleeve Lobectomy and Pneumonectomy8:49

Thoracotomy Versus Minimally Invasive Approaches for Lung Cancer Resection11:39

Palliative Surgery For Stage IV Lung Cancer - Tracheal and Pleural Disease9:36

Chest Wall Resection16:55

Metastasectomy of Cancer Spread to the Lung7:06

Peri-Operative Evaluation and Fitness6:41

Complications After Lung Cancer Surgery20:06

Meet the Instructors

Dr. Leslie Eisenbud Quint
Course Co-director, Professor of Radiology and Professor of Surgery, Section of Thoracic Surgery
Medical School
Dr. Rishindra Reddy
Course Co-director, Assistant Professor of Surgery, Section of Thoracic Surgery
Medical School
Dr. Gregory Kalemkerian
Course Co-director, Professor of Medicine, Division of Hematology/Oncology
Medical School
Thoracic Oncology team at the University of Michigan

The objective of this talk is to provide some basic information on

the definitive treatment of stage 1 non-small cell lung cancer with

external beam radiation therapy.

The pre-lecture questions is, the optimal treatment for

a patient with Stage 1 non-small cell lung cancer and poor pulmonary function is?

A.Wedge resection, B.Lobectomy,

C.stereotactic body radiation therapy, commonly known as SBRT.

D, unclear if wedge or SBRT.

Or E, none of the above.

So in talking about stage one, non-small cell lung cancer,

what that means is that there is just the primary tumor in the lung.

There's no lymph node involvement, and that Is what is indicated in this picture.

Terms of the management of Stage I, non-small cell lung cancer: surgery is

generally considered the standard approach.

And the surgery can be done in one of two ways.

It can be done as a lobectomy which means they remove the lobe of the lung or

a wedge resection, sometimes referred to as a segmental resection.

Where they're just removing a portion of the lobe of the lung.

But not all patients are candidates for or desire surgery and in that case,

consideration could be given to treating them with either conventionally

fractionated therapy or stereotactic body radiation therapy.

Which is, again, referred to by the acronym SBRT or

sometimes also the acronym SABR, but these both mean the same thing.

So, when you look at Lobectomy versus Wedge Resection these are some data

that were published back in the mid 90s.

It was a study that was done by the Lung Cancer Study Group and

they compared Lobectomy to a more limited resection,

generally referred to, again, as a Wedge Resection.

And what they found was that for patients who had a Lobectomy there

was a decrease in likelihood of recurrence as compared to a more limited resection.

But that the overall survival was the same.

And most people feel that if a lobectomy could be done safely that would be

the prefered approach to again reduce this likelihood of a local reoccurrence.

So what about SBRT for a non small cell lung cancer?

The idea behind this treatment is that it's intended

to deliver an ablative dose of radiation to the tumor.

And as I mentioned in a prior lecture,

we're going to give a much higher biological dose than we would be giving

with conventionally fractionated radiation therapy.

So for SBRT, we might use a dose for 54 gray in three 18 gray fractions.

Which has a biologically equivalent dose of 151 gray and

if you compare that to conventionally fractionated radiation therapy.

Which again is 60 gray so

its going to be 30 treatments of 2 gray for a total of 60 gray.

The idea too with SBRT is that because we are treating a much smaller volume and

really only focusing on the primary tumor.

The tumor in the lung, and not any lymph nodes, for instance.

We can get a much higher dose to the tumor, and

limit the dose to most normal tissues to doses that are considered safe.

This is just a picture, a diagram, from a treatment planning system

showing how we go about delivering a SBRT for an early stage lung cancer.

So at the bottom of the slide you'll see a green line.

That's actually a contour on a CT scan that's been fused of the spinal cord.

The tumor is just in this view, just above that in pink.

And then, you can see there's a linear pink structure above that,

which is the esophagus, and then the red structure is the heart.

And what you can see is that there are, I think in this plan, 11 beams.

Coming in from different directions,

all of which are centered on the target, the tumor that we're treating.

And so what that means is that if we look at the next slide,

this is a dose distribution of what the radiotherapy looks like for

stereotactic body radiation therapy.

There's a very high concentration of dose

around the tumor which you can see in this case is around the right lower lobe.

And I should mention that when we create targets for

this type of treatment, it's not just the tumor that we are targeting but

we also need to put some margin around the target.

That takes into account any slight variation in patient position,

also gives us room to get a sufficient dose to the tumor itself.

But as you can see as we get what is sort of equivalent to a topographical

map of the dose, where around the tumor there's a very high concentration of dose.

And then as we move away, just even a few millimeters from the edge of

the area that we're targeting, the dose falls off very quickly.

And that helps us to minimize the dose of radiation

to the surrounding normal tissues.

So when it comes to delivering stereotactic body radiation therapy for

non small cell lung cancer.

When we do the treatment planning, as I mentioned earlier in the previous lecture.

We do a motion assessment,

with a four dimensional CT, where the fourth dimension is time.

And that's going to allow us to assess whether or

not the tumor moves a lot when the patient is breathing.

As you might imagine, tumors in the upper lobes tend to move less.

Whereas tumors that are in the lower lobes,

closer to the diaphragm tend to move more.

So we can assess that motion and then we can decide whether or not we need to

manage that motion, if it's above a certain threshold say a centimeter.

And we can do that either by restricting the patients breathing through abdominal

compression.

We can use a gating technique for instance,

where we would hold the patients breath.

At a certain reproducible point in the breathing cycle, and

then turn the machine on during that breath hold.

And there are even some very sophisticated systems for tracking the motion so that

the machine can sort of move the tumor and track it during the breathing cycle.

And then another important aspect of the treatment is,

during the treatment we use image guidance, so

that we have the capability on the treatment machine to do a CT scan.

And we can use that information and compare it to the planning

a process to help us to localize the tumor within millimeters.

And then also their are systems that allow us to monitor the patient

while the treatment is actually is being delivered to

make sure that the patient hasn't moved for instance.

So these are some data about the use of stereotactic body radiation therapy for

inoperable early stage lung cancer.

This was a study that was done by the radiation therapy oncology group.

It was a phase two multicenter study, where they looked at the use of SBRT for

peripheral, early stage lung cancers, and

used the fractionation schedule that I mentioned earlier of 18 gray times three.

And there were 55 patients that were treated in this study, and

as you can see the local control at three years was extremely high, over 97%.

There were some patients that had failures in untreated mediastinal nodes,

but that was low.

Unfortunately, with lung cancer patients can develop metastatic disease, so

the disease-free survival at three years was around 50%.

But the three year overall survival was 55%.

So generally speaking, when it came when one compares the use of SBRT for

conventionally fractionated radiation therapy for early stage on lung cancer.

The tumor control is much higher than what we would expect and so

this is really when these data were published.

Quite exciting when thinking about how to use radiotherapy to treat

early stage lung cancer.

So the next question that might obviously come to mind is well,

that might be very good for inoperable patients, what about operable patients?

Do we have any data that we can use to compare SBRT to a Wedge resection.

And so these are some data that were published about five years ago now,

from Beaumont Hospital in Royal Oak Michigan.

And what they did in this study was they retrospectively compared about 70 patients

treated with surgery to about 60 patients treated with radiation therapy.

The follow up was relatively short, only about two and a half years.

But what they found, if you look at the local control graph on the left was

that the local control appeared to be higher for SBRT than for wedge resection.

Which again hearkens back a little bit to that data that I showed you earlier

showing increased likelihood of local recurrence in

patients that have wedge versus lobectomy.

And then when you look at cause specific survival,

it didn't appear that the use SBRT was any worse than wedge resection.

These are some data that are a little bit more recent, published just last year,

that compare a lobectomy to SBRT for operable lung cancer again.

Unfortunately, as you might imagine such a trial can be difficult to carry out,

randomizing patients between surgery and radiation.

And so, this was actually a meta analysis of two studies that were done.

One that was in the US and the other

in Europe that failed to meet their accrual goals and closed quite early.

And unfortunately, only in total randomized about 30 patients

to radiation and 30 patients to surgery.

But interestingly enough,

if we look at the data on the left is a graph looking at local control.

And you can see that surgery and radiation were equivalent but

looking at the graph on the right and looking at overall survival.

There was actually an improvement in overall survival

associated with the use of radio therapy as compared to surgery.

And so while this meta-analysis just contained over about

60 patients, that's hard to draw any firm conclusions,

but at least these data are hypothesis generating.

And suggest that at least maybe there's not a decrement to the use

of SBRT as compared to lobectomy for patients who are surgical

candidates who have stage one non-small cell lung cancer.

So to follow up on that, as far as take home points, I think most people would

agree that surgery is still considered the standard treatment for

operable stage I non-small cell lung cancer.

But there are growing data supporting the use of SBRT for

sure in inoperable patients and even some suggestive data in operable patients.

So the post-lecture question is, the optimal treatment for

a patient with stage I non-small cell lung cancer and poor pulmonary function is?

A.a wedge resection.

B, Lobectomy.

C.SBRT.

D.Unclear if a wedge would be better than SBRT.

And E.

None of the above.

And the answer is D, I think it's still unclear if a wedge resection or

SBRT is going to be the best option for a patient in these circumstances.

Thanks for listening, and the next lecture, I'm going to talk about

the use of radiotherapy for locally advanced non-small cell lung cancer.

Explore our Catalog

Join for free and get personalized recommendations, updates and offers.

Coursera provides universal access to the world’s best education, partnering with top universities and organizations to offer courses online.

© 2019 Coursera Inc. All rights reserved.

Download on the App Store

Get it on Google Play